CapitolRadar tracks every publicly disclosed DGX trade by US congress members and corporate insiders: 17 disclosed trades (6 buys, 11 sells) by 4 tracked traders, from 2021-03-29 to 2026-09-04. Updated daily from official filings.
Want a ping when Congress buys DGX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Quest Diagnostics Incorporated (DGX) — Healthcare · Medical - Diagnostics & Research, market cap about $25.8B.
CapitolRadar analysis
17 disclosed DGX trades: 6 buys and 11 sells
17 tracked trades in Quest Diagnostics Incorporated (DGX) span March 29, 2021 through September 4, 2026. The activity comprises 6 buys and 11 sells by 4 distinct traders, so sells represent the larger share of this small sample. The supplied data does not identify which traders made the 11 sales or distinguish between categories of trader beyond the named buyers. DGX is classified in Healthcare, within Medical - Diagnostics & Research.
7 trades in 2022 Q1 dominate the listed quarterly counts
2022 Q1 contains 7 trades, including 1 buy, making it the busiest quarter shown. The other listed periods are much lighter: 2024 Q1 has 2 trades and no buys, while 2023 Q2, 2023 Q3, 2023 Q4, 2024 Q4, 2025 Q1 and 2026 Q3 each have 1 trade. The single trades in 2023 Q2, 2023 Q4, 2024 Q4 and 2026 Q3 were buys; those in 2023 Q3 and 2025 Q1 were not. With only 17 trades overall and several one-trade quarters, quarter-to-quarter comparisons rest on small samples.
5 of 6 buys are attributed to Ro Khanna
Ro Khanna accounts for 5 tracked DGX buys, with the latest dated September 4, 2026. Tommy Tuberville accounts for 1 buy, dated March 29, 2021. For each of AMD, BAX, CASY, COF, CVS and ETN, 1 of these DGX buyers also recorded a buy; the facts do not establish that the same buyer appears across all six symbols or provide timing and size for those transactions.
Disclosures can arrive up to 45 days after a transaction, so reported activity may not be current when published. Transaction amounts are not provided here; any amount ranges shown elsewhere are estimates rather than exact values. The limited number of trades and traders also makes broad conclusions about trading patterns uncertain.
Analysis written from the tracked record on 2026-10-13; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 1 | 1 | 0 |
| 2025 Q1 | 1 | 0 | 1 |
| 2024 Q4 | 1 | 1 | 0 |
| 2024 Q1 | 2 | 0 | 2 |
| 2023 Q4 | 1 | 1 | 0 |
| 2023 Q3 | 1 | 0 | 1 |
| 2023 Q2 | 1 | 1 | 0 |
| 2022 Q1 | 7 | 1 | 6 |
Who is buying DGX?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 5 | 2026-09-04 | — |
| Tommy Tuberville | 1 | 2021-03-29 | — |
Disclosed trades in DGX
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-03-10 | Carol Devine Miller | sell | $15,001 - $50,000 | — |
| 2024-11-15 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-02-13 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-01-03 | Tommy Tuberville | sell | $15,001 - $50,000 | — |
| 2023-10-31 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-09-06 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-06-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2022-03-31 | Michael McCaul | sell | $50,001 - $100,000 | — |
| 2022-03-31 | Michael McCaul | sell | $100,001 - $250,000 | — |
| 2022-02-17 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2022-01-28 | Michael McCaul | sell | $1,001 - $15,000 | — |
| 2022-01-21 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2022-01-20 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2022-01-07 | Michael McCaul | sell | $15,001 - $50,000 | — |
| 2021-12-14 | Michael McCaul | sell | $1,001 - $15,000 | — |
| 2021-03-29 | Tommy Tuberville | buy | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-08-31
Quest Diagnostics SVP and General Counsel Michael E. Prevoznik disclosed a roughly $2.54 million DGX stock purchase. The panel passed mainly because he has no verified trading history, so even this large, promptly disclosed buy remains an unproven signal. A documented record of his prior purchases outperforming SPY would have strengthened the case enough to change the verdict.
These buyers also bought
Other stocks the tracked buyers of DGX disclosed buying in the last six months: ACGL (1) · AMT (1) · BIIB (1) · CCL (1) · COR (1) · DHI (1).
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its ext…
Frequently asked questions
Which politicians bought DGX most?
Ro Khanna leads with 5 disclosed buys, followed by Tommy Tuberville.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.